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Summary To estimate the prevalence of TP53mutations in familial breast cancer, constant denaturant gel electrophoresis (CDGE) was used
to screen exons 5-8 of the TP53gene for germline mutations. Genomic DNA from 128 breast cancer patients belonging to 109 families with
familial cancer were screened. No germline mutations were found in any of the patients. We also studied TP53mutations in tumour DNA from
51 of the same individuals and found mutations in 14%. This is similar to what has been reported in sporadic breast cancer.
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The p53 protein is a transcription factor and is frequently altered
by mutation in most types ofcancer. The majority ofthe mutations
are missense mutations (Hollstein et al, 1994).
Germline mutations in the TP53 gene were found to segregate
in families with the Li-Fraumeni syndrome resulting in a very
high risk for early onset breast cancer, sarcoma, leukaemia, brain
tumours and other tumours (Malkin, 1994; Wang et al, 1995). It
has also been shown that not all families with the classical criteria
for Li-Fraumeni segregate a mutation in p53, while some other
families with non-classical Li-Fraumeni syndrome do (Birch et al,
1994). Germline mutations have also been found in families with
breast and ovarian cancer (Prosser et al, 1992; Jolly et al, 1994).
However, germline mutations have not been found to segregate
frequently in breast cancer families or patients with early onset or
bilateral disease (Prosser et al, 1991; Sidransky et al, 1992;
B0rresen et al, 1992; Lidereau and Soussi, 1992).
One study, which compared the frequency of somatic TP53
mutations in sporadic breast carcinomas with tumours from
patients with a family history, showed that, while sporadic TP53
mutations occurred in 13% ofthe sporadic tumours, the frequency
in the familial cases was 58% (Glebov et al, 1994).
We have used constant denaturant gel electrophoresis (CDGE)
to screen for germline mutations in exons 5-8 of the TP53 gene
in members from 109 breast cancer families. This study also
involved searching for mutations in 51 of the tumours from our
patients with familial breast cancer.
MATERIALS AND METHODS
Patients
A total of 128 patients from 109 families with familial cancer,
predominantly breast cancer, were identified. The families were
selected as described (Lindblom et al, 1992a). Based on the
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number of breast cancer and other cancer diagnoses, the families
were categorized as follows: 45 families were defined as breast
cancer families and 25 families were defined as cancer families
using the following criteria. Breast cancer family - at least three
first- or second-degree relatives with breast cancer. Cancer family
- the index patient with breast cancer plus at least three first- or
second-degree relatives with cancer. The remaining 39 families
had a family history of two first-degree relatives with breast
cancer. Tumour tissue was available from 51 ofthese patients.
Loss of heterozygosity (LOH)
Blood and tumour samples from the patients were obtained. All
tumours had been surgically removed before radiation or
chemotherapy and fresh specimens were frozen at -70°C, and
stored for periods varying from 6 months to 12 years before DNA
isolation. Constitutional and tumour genotypes were compared
by using restriction fragment length polymorphism (RFLP)
analysis: D17S5/YNZ22.1 with RsaI on the distal part of 17p;
D17S31/MCT35 withMspI at the TP53 locus. A polymerase chain
reaction (PCR)-based intragenic p53 marker involving a CA
repeat polymorphism (Ishimaru et al, 1994) was also used to study
LOH. Allelic loss was detected as either a total absence or a
reduced signal intensity (<50%) of one of the constitutional
alleles as scored by the naked eye. When necessary this was
confirmed by densitometry. Tumours were analysed with respect
to the number of normal cells compared with malignant cells on
representative slides. These estimates were coded by an indepen-
dent pathologist.
All the conditions and PCR primers (shown in Figure 1) for
CDGE have been described previously (B0rresen et al, 1991;
Smith-S0rensen et al, 1993; Andersen et al, 1995). A specific
analysis was made to identify a frequently described G to C muta-
tion in codon 156. The exon 5 was amplified using the same
primers (covering codon 126-160, Figure 1) as were used in the
CDGE analysis. Then, the fragment was cut by the restriction
enzyme BstUI. The wild-type fragment contained one BstUI
restriction site, which disappeared in the mutated fragment.
Separation of the fragments was performed using polyacrylamide
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Figure 1 Genomic map of the TP53 gene, exons 5-8. Arrows show the primers position. Numbers below correspond to basepair numbers in the genomic DNA;
numbers above the arrows correspond to codon numbers
Figure 2 Restriction enzyme analyses to detect mutations in codon 156 Figure 3 CDGE gel of exon 7 of the TP53 gene showing 12 tumours and
of the TP53 gene. The BstUl-digested products were separated in 15% seven blood samples. M61, M89 and Ham34t are tumours showing
polyacrylamide gel. As a negative control, DNA from normal leucocytes was alterations. The control is an artificial mutation generated using a mutated
used (N). As a positive control (M), an artificial mutant was created using PCR primer (Borresen
et al, 1991; Smith-Sorensen et al, 1993; Andersen
a mutant PCR primer. A wild-type allele results in three DNA fragments: et al, 1995). The gel was run for 3 h at 560C using 43% denaturant (100%
117 bp, 67 bp and 7 bp. A mutant allele results in two fragments: 124 bp denaturant: 7 M urea, 40% formamide)
and 67 bp
Table 1 Primers used for sequencing
Exon Sense primer Antisense primer
5 5'-biotinGGTGCTTACACATGTTTGTTTCTTTG-3' 5'-GCTGCTCACCATCGCTATCTG-3'
5'-biotinGCCATCTACAAGCAGTCACAG-3' 5'-GCCAGACCTAAGAGCAATCAG-3'
6 5'-biotinTTCAACTCTGTCTCCTTCCT-3' 5'-CGGAGGGCCACTGACAACCA-3'
5'-TTAACCCCTCCTCCCAGAGA-3'a
7 5'-biotinAGGCGCACTGGCTCATCTT-3' 5'-GGGGTCAGCGGCAAGCAGA-3'
5'-TGTGCAGGGTGGCAAGTGGC-3'a
aAn internal primer to be used in the sequencing reaction.
gel electrophoresis (Figure 2), and the wild-type and mutant codon
156 could be distinguished.
Sequencing
Exon 5 was divided into two overlapping fragments for
sequencing (Figure 1 and Table 1). Forboth exons 6 and 7, one pair
ofprimers was used forthe PCR and an internal primer was used to
sequence the PCR product (Figure 1 and Table 1). In all cases,
genomic DNA was used as the template to amplify the fragment
with the PCR primers. Rapid PCR sequencing method (Murray,
1989) or biotin streptavidin sequencing method (Syvanen et al,
1989) ofPCR products were performned.
RESULTS
CDGE was used to screen exons 5-8 for germline mutations in
128 patients from 109 families with familial cancer. No germline
mutations were found. Heterozygosity for a known polymorphism
in codon 213 (A-*G), which does not result in any change in the
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Table 2 p53 mutations in familial breast carcinomas
Familyttumour Exon Mutation Loss of heterozygositya
D17S5 D17S31 p53
2027/M11 5 Codon 173, GTG-*TTG 0 0 +
5/M68 5 Codon 173, GTG-*CTG + 0 0
1227/M16 6 Codon 213, C-J, stop - 0 0
1613/M22 6 Codon 213, C-*T, stop 0 0 -
1306/M61 7 Deletion G in position 857 0 - 0
205/M89 7 Codon 238, TGT-*AGT - - 0
3003/Ham34t 7 Codon 256, ACA-*TCA + + 0
ao, not informative; +, retention; -, loss.
A B
G A T C G A T C G A T C G A T C
'U. -a'.L
1b1 .1111~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.:'._2_..........!:
W.
4Ew
Figure 4 (A) Sequence analyses of exon 7 showing the frameshift mutation in tumour M61 (biotin-streptavidin sequencing method). (B) Sequence analyses of
exon 6. Samples from left to right, Ml16, M22 and a normal control. Ml16 and M22 samples show the nonsense C to T mutation (in the figure, antisense strand
showing a G to A, biotin-streptavidin sequencing method)
amino acid, was found in four of the 128 patients and in one close a serine, and another in codon 256 (A-*T), which alters a threo-
relative with breast cancer. nine to a serine. We also found one tumour with a deletion of a G
Sequence alterations were detected by CDGE in seven out of at position 857 in codon 251 resulting in a frameshift mutation
51 of the tumour DNA samples screened (Table 2). Two tumours (Figures 3 and 4A).
had a missense mutation in codon 173, GTG-4TTG and A common mutation in codon 156 in exon 5 is not detected by
GTG-~CTG, leading to the same amino acid change (valine to CDGE using the conditions described. Therefore, a specifi'c test
leucine). Two tumours showed a C-*T change in codon 213 in using restriction analysis with BstUI enzyme was performed to
exon 6 resulting in a stop codon. In exon 7, we found two missense screen for this particular mutation (Figure 2). No mutation was
mutations, one in codon 238 (T-*A), which changes a cysteine to found.
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We also analysed all tumours forLOH using three markers. One
of these, D17S5, is located distally on chromosome 17p. This
marker has frequently been used in LOH studies in breast cancer.
Another marker, D17S31, is located close to the TP53 gene and a
third one is intragenic. The results from the first two markers have
been published previously (Lindblom et al, 1992b). The overall
result showed LOH distal on 17p, D17S5 region, in 22% of the
tumours. Using the intragenic p53 marker, eight of35 informative
tumours showed LOH (23%) and when both D17S31 and the
intragenic p53 marker were used, 33% of the tumours displayed
LOH in the p53 region. The tumours with p53 mutations and their
LOH data are shown in Table 2.
DISCUSSION
Some studies have suggested that the tumour-suppressor gene,
TP53, is involved in approximately 1% of familial breast cancer
cases (Prosser et al, 1991; Sidransky et al, 1992; B0rresen et al,
1992; Lidereau and Soussi, 1992). We studied patients from 109
breast cancer families and found no germline mutation in p53,
confirming this low frequency. This means that there is little or no
clinical benefit in screening patients from families with a history
ofprimary breast cancer forgermline mutations in p53. Only a few
ofour families have germline mutations in theBRCAJ (Miki et al,
1994) and BRCA2 (Wooster et al, 1995) genes (unpublished
results). Therefore, it is possible that in most of these families
other breast cancer susceptibility genes may be segregating,
increasing the overall risk. These genes are still to be identified.
The frequency ofsomatic mutations in these familial tumours is
not different from that ofsporadic breast tumours, whereas the rate
ofmutations is between 15% and 25%. The specific G to C muta-
tion in codon 156 of the TP53 gene that was found in 44% ofthe
tumours from familial cases in a previous study (Glebov et al,
1994) is not seen in this cohort of patients. In a cohort of 88
Norwegian familial breast cancercases, this mutation was found in
the tumours from two cases (unpublished results). These results
suggest that this particular mutation is not a main hotspot for
mutation in familial breast cancer cases, nor does this reflect a
difference between populations.
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